Duarte Goncalves Machado MD
Assistant Professor of Neurology; Lead Neurologist, Yale Health Center
Clinical trials for early and advanced Parkinson's disease; New indications of botulinum toxins in clinical neurology, including pain, restless leg syndrome, adn tremor, etc; Novel applications of deep brain stimulation
Extensive Research Description
My research interest is focused on the discovery and evaluation of new treatments that aim at better management of symptoms of Parkinson’s disease and other movement
disorders. I was involved in two phase III studies to evaluate the safety and efficacy of IPX066 (carbidopa-levodopa extended release) in early and advanced Parkinson’s disease, a product which has recently been approved by FDA. I am also involved in clinical trials of botulinum toxins in movement disorders and pain, with my focus being on a study to evaluate the efficacy and safety of incobotulinum toxin-A in essential tremor.
1. Jabbari B and Machado DG. Treatment of refractory pain with botulinum toxins - An evidenced based review. Pain Medicine 2011: 12(11):1594-1606.
2. Jabbari Band Machado DG. Clinical Use of Botulinum Neurotoxins: Pain. Chapter 19 in Botulinum Neurotoxin – Molecular Understanding and Its Application, ed K Foster. Springer, 2012.
I am also interested in the application of modern neuroimaging methods, including positron emission tomography (PET), to understand the pathophysiology of movement disorders. My current research projects include a study to assess the safety, tolerability,
pharmacokinetics, biomarker effects, efficacy, and effect on microglial activation of AZD3241 in subjects with multiple system atrophy (MSA). AZD3241 is a potent, selective, brain-permeable myeloperoxidase (MPO) inhibitor. MPO generates an array of cytotoxic oxidants, and data indicate that MPO produces such oxidants in MSA. An MPO inhibitor such as AZD3241 may inhibit the generation of cytotoxic oxidizing species in patients with MSA, potentially slowing neurodegeneration. Working in collaboration with investigators in Yale Diagnostic Radiology, this study is aims to understand the effects of AZD3241 on microglial activation as assessed via PET measured by [11C]PBR28 binding.